More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$941183242
EPS
-1.89
P/E ratio
--
Price to sales
19.85
Dividend yield
--
Beta
1.381408
Previous close
$6.17
Today's open
$6.17
Day's range
$6.06 - $6.31
52 week range
$6.06 - $12.41
show more
CEO
Harpreet Singh,
Employees
589
Headquarters
Tbingen,
Exchange
NASDAQ Capital Market
Shares outstanding
149631676
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Immatics Announces Third Quarter 2026 Financial Results and Business Update
Houston, Texas and Tuebingen, Germany, November 10, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today provided a business update and reported financial results for the quarter ended September 30, 2026.
GlobeNewsWire • Nov 10, 2026

Immatics (IMTX) Reports Q3 Loss, Lags Revenue Estimates
Immatics (IMTX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.49 per share a year ago.
Zacks Investment Research • Nov 10, 2026

Immatics (IMTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Nov 9, 2026

Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Houston, Texas and Tuebingen, Germany, October 24, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced updated clinical trial data from its ongoing Phase 1b study with IMA402 PRAME bispecific and its Phase 1 study with IMA203CD8 PRAME cell therapy.
GlobeNewsWire • Oct 24, 2026

Immatics Announces $150 Million Underwritten Offering
Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced today that it has agreed to sell 12,945,916 ordinary shares at $8.69 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 4,315,304 ordinary shares at a purchase price of $8.689 per pre-funded warrant, which represents the per share offering price less the $0.001 per share exercise price for each pre-funded warrant, in an underwritten offering.
GlobeNewsWire • Aug 25, 2026

Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma
Immatics N.V. is rated "Buy," downgraded from "Strong Buy," due to partial partnership termination and pivotal trial dependency. IMTX's investment thesis centers on anzu-cel [IMA203], a PRAME-directed TCR therapy in phase 3 SUPRAME for 2nd-line melanoma, with final PFS data expected in H1 2027. Positive phase 1b data [56% cORR, 6.1m PFS] and expansion into metastatic uveal melanoma support label expansion and broader PRAME pipeline ambitions.
Seeking Alpha • Aug 25, 2026

Immatics Announces Second Quarter 2026 Financial Results and Business Update
Houston, Texas and Tuebingen, Germany, August 18, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today provided a business update and reported financial results for the quarter ended June 30, 2026.
GlobeNewsWire • Aug 18, 2026

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
Houston, Texas and Tuebingen, Germany, July 17, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced three presentations at the European Society for Medical Oncology (ESMO) Congress 2026, to be held from October 23-27, 2026, in Madrid, Spain.
GlobeNewsWire • Jul 17, 2026

Immatics: PRAME Is Becoming More Than A Single-Asset Story
Immatics is evolving into a PRAME-focused oncology platform with three monetization paths, not just a single-asset cell therapy play. IMTX's lead asset, anzu-cel, is in Phase 3 for advanced melanoma, but broader value lies in its layered PRAME franchise and pipeline expansion. IMTX maintains a strong cash runway into 2028, enabling critical clinical milestones without distressed financing or near-term capital risk.
Seeking Alpha • Jun 16, 2026

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Houston, Texas and Tuebingen, Germany , June 1, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced extended data from the ongoing Phase 1b clinical trial evaluating anzu-cel (anzutresgene autoleucel, IMA203) PRAME TCR T-cell therapy in heavily pretreated patients with advanced melanoma in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, USA. The dataset is focused on patients treated with anzu-cel at the recommended Phase 2 dose (RP2D), including longer follow-up and further characterization of the durability and systemic nature of the observed clinical responses.
GlobeNewsWire • Jun 1, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Immatics N.V. commission-free¹. Build wealth for the long term using automated trading and transfers.